These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Earnings

robot
Abstract generation in progress

Quest Diagnostics (NYSE: DGX) reported strong first-quarter earnings, beating analyst expectations for both adjusted earnings per share and sales. Following these results, the company raised its fiscal 2026 adjusted EPS and sales guidance. Several analysts subsequently increased their price targets for Quest Diagnostics, including Truist Securities, Barclays, and Baird.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin